SymBiosis Capital Partners, LLC - Stock Holdings in 13F Filings (SEC)

Updated on March 15, 2026.

Based on 13F Filings filed with the SEC on February 12, 2026, for the 2025 Q4 period, SymBiosis Capital Partners, LLC held in its portfolio 11 assets valued at $109,495,134 (i.e. $109.50M).

The most valuable assets in the portfolio included: Evommune, Inc. ($21.93M), Verastem Inc ($15.44M), and Aldeyra Therapeutics Inc ($13.24M).

The chart below shows the top 10 valuable assets, and the table below shows the top 11 valuable assets.

You can see similar for other investment managers.

Related Topics: SEC Topic List.

Data Source: SEC.

Top Valuable Stocks in SymBiosis Capital Partners, LLC Portfolio

Evommune, Inc.

Verastem Inc

Aldeyra Therapeutics Inc

Precigen Inc

Inventiva S.A.

Nuvation Bio Inc

Rani Therapeutics Holdings, Inc.

Aardvark Therapeutics, Inc.

Clene Nanomedicine Inc.

Generation Bio Co

SymBiosis Capital Partners, LLC - Stock Holdings in 13F Filings (SEC)

Items per page:

0 of 0

Name of Issuer	No. of Shares	Value ($)	Class
Evommune, Inc.	1280778	21926919	COM SHS
Verastem Inc	2000000	15440000	COM NEW
Aldeyra Therapeutics Inc	2555000	13234900	COM NEW
Precigen Inc	3000000	12540000	COM
Inventiva S.A.	2600000	12090000	ADS
Nuvation Bio Inc	1250000	11200000	COM CL A
Rani Therapeutics Holdings, Inc.	6300000	8505000	COM CL A
Aardvark Therapeutics, Inc.	476595	6255309	COM
Clene Nanomedicine Inc.	770495	4522806	COM NEW
Generation Bio Co	665000	3777200	COM NEW
Surrozen, Inc.	150000	3000	*W EXP 08/01/203